• Biologics
    • Modalities
      • Mammalian
      • Microbial
      • ADCs / Bioconjugates
      • mRNA / LNP
      • Drug Product
    • Technologies & Products
      • Expression Technologies
      • Discovery Products
      • Bioprocessing Products
    • Discovery and Preclinical
      • Early De-risking & Optimization
      • Cell Line & Strain Development
      • Process Development & Optimization
      • Analytical Development
      • Formulation Development
      • Non-GMP Manufacture
    • Clinical and Commercial
      • Process Development & Optimization
      • Formulation Optimization
      • cGMP Drug Substance Manufacture
      • cGMP Drug Product Manufacture
    Technical Support
    Regulatory Support
    View all locations
    View all Biologics offerings
    Woman and microscope

    Knowledge Center

    View all the latest resources available on site


    Visit our Knowledge Center

  • Small Molecules
    • Services
      • Drug Substance (API)
      • Particle Engineering
      • Drug Product
    • Technologies
      • Highly Potent API (HPAPI)
      • ADCs
      • Spray Dried Dispersions
      • Micronization & Jet Milling
      • Inhaled Delivery (DPI)
    • Solutions
      • Early Phase API
      • Commercial Production API
      • Bioavailability Enhancement
      • Integrated Offerings
    • Knowledge Center
      • Webinars
      • Presentations
      • Publications
      • Meet the Experts
      • View all
    View all Small Molecules offerings
    View all locations
    Clinical drug development & preformulation

    Knowledge Center

    View all the latest resources


    Visit our Knowledge Center

  • Cell & Gene
    • Services
      • Process Development
      • cGMP Manufacturing
      • Regulatory Consulting
      • Bioassay Services
      • Tissue Acquisition
    • Modalities
      • Autologous
      • Allogeneic
      • Viral Vectors
      • iPSCs
      • Exosomes
    • Technologies
      • MODA® Platform
      • Cocoon® Platform
      • Nucleofector® Technology
      • TheraPEAK® Media
      • Endotoxin and Pyrogen Testing
    • Knowledge Center
      • Webinars
      • Articles
      • Whitepapers & Publications
      • eBooks
      • Presentations
      • View all
    View all Cell & Gene offerings
    View all Bioscience Products
    View all locations
  • Capsules & Health Ingredients
    • Health Ingredients
    • Nutraceutical capsules
    • Pharmaceutical capsules
    • Capsule filling equipment
  • Contact
  • Trending Topics
    New Cambridge, USA Lab Expands Our Early De-risking Capacity
    Upcoming Conference PEGS Boston 2023, USA
    New Whitepaper: Optimization of mRNA Manufacturing
    Shaped Around You - Committed to your molecule’s IND
    New Whitepaper: Late-Phase Drug Product Development and Launch
Trending Topics
New Cambridge, USA Lab Expands Our Early De-risking Capacity
Upcoming Conference PEGS Boston 2023, USA
New Whitepaper: Optimization of mRNA Manufacturing
Shaped Around You - Committed to your molecule’s IND
New Whitepaper: Late-Phase Drug Product Development and Launch
Biologics
Biologics
Modalities
  • Mammalian
  • Microbial
  • ADCs / Bioconjugates
  • mRNA / LNP
  • Drug Product
Technologies & Products
  • Expression Technologies
  • Discovery Products
  • Bioprocessing Products
Discovery and Preclinical
  • Early De-risking & Optimization
  • Cell Line & Strain Development
  • Process Development & Optimization
  • Analytical Development
  • Formulation Development
  • Non-GMP Manufacture
Clinical and Commercial
  • Process Development & Optimization
  • Formulation Optimization
  • cGMP Drug Substance Manufacture
  • cGMP Drug Product Manufacture
Back
Small Molecules
Small Molecules
Services
  • Drug Substance (API)
  • Particle Engineering
  • Drug Product
Technologies
  • Highly Potent API (HPAPI)
  • ADCs
  • Spray Dried Dispersions
  • Micronization & Jet Milling
  • Inhaled Delivery (DPI)
Solutions
  • Early Phase API
  • Commercial Production API
  • Bioavailability Enhancement
  • Integrated Offerings
Knowledge Center
  • Webinars
  • Presentations
  • Publications
  • Meet the Experts
  • View all
Back
Cell & Gene
Cell & Gene
Services
  • Process Development
  • cGMP Manufacturing
  • Regulatory Consulting
  • Bioassay Services
  • Tissue Acquisition
Modalities
  • Autologous
  • Allogeneic
  • Viral Vectors
  • iPSCs
  • Exosomes
Technologies
  • MODA® Platform
  • Cocoon® Platform
  • Nucleofector® Technology
  • TheraPEAK® Media
  • Endotoxin and Pyrogen Testing
Knowledge Center
  • Webinars
  • Articles
  • Whitepapers & Publications
  • eBooks
  • Presentations
  • View all
Back
Capsules & Health Ingredients
Capsules & Health Ingredients
Health Ingredients
Nutraceutical capsules
Pharmaceutical capsules
Capsule filling equipment
Back
Contact
Back
  • Home
  • Biologics
  • Mammalian Biopharmaceutical Services
  • Ibex® Design | Standard mAbs DNA-to-IND Program

Ibex® Design 2.0
Standard mAbs
DNA-to-IND Program

Ibex® Design 2.0 is our new fixed price, fastest DNA-to-IND program that minimizes risk and uncertainty. This improved version utilizes advanced technologies to further shorten timelines, increase specific productivity and enhance product yield for standard monoclonal antibodies.
Talk to our team about Ibex® Design
5 Months* from DNA to TOX Drug Substance.
11 Months* from DNA to IND/IMPD.
Minimum 1.5kg GMP Drug Substance.

Ibex® Design 2.0: Speed and quantity guaranteed* at a fixed price

Ibex® Design 2.0 is a new comprehensive program combining speed, guarantees* and quality while minimizing risk, in the delivery of your CMC path to IND in only 11 months for your monoclonal antibodies.

If you are looking to gain maximum information on your drug candidate as early as possible, Ibex® Design delivers tox drug product in only 5 months so that you can perform toxicological studies before entering GMP manufacturing.

Our parallel cell line and drug substance process development, as well as our integrated drug substance and drug product program, are key to bringing your rapidly quickly to the clinic. In addition, our step-by-step development strategy will allow balancing your program’s speed to your funding milestones.

Once you enrol in our Ibex® Design program, we will keep a manufacturing slot reserved for your clinical resupply and offer flexible drug product manufacturing, to further increase predictability in achieving timelines and material supply.

*For antibodies. From DNA transfection. Subject to terms and conditions.

We are equipped to support your molecule’s progression by overcoming barriers or finding innovative solutions using advanced technologies.

The quality of our early material generated from stable pool is representative of material generated later in the workflow from the selected clonal cell line (research cell bank). This allows us to use pool material to develop the purification process and formulation as soon as possible, achieving a parallel cell line and drug substance process development. This is one of the key elements to save time early, without increasing development risks, and help you accelerate your path to clinic.

We implement this platform development approach combined with state-of-the-art process platforms with the end point in mind, to ensure a direct and seamless transfer to cGMP manufacturing at 1 kL scale.

Related Offering

Bispecific Antibodies DNA-to-IND Program
We provide an integrated drug substance/drug product DNA to IND program with reliable timelines...
Learn More
Fabs, Fusion, Scaffold and Other Recombinant Proteins DNA-to-IND Program
We will screen more clones to find the highest titer clone. The offering is suitable for customers...
Learn More
Mammalian Cell Line Development
Benefit from our flexible approach to cell line development matching your project’s priorities in...
Learn More
Mammalian Process Development
We provide access mammalian cell culture process development, optimization and validation services...
Learn More
Mammalian Analytical Development
We provide analytical capabilities encompassing a wide range of technologies to support all stages...
Learn More
Mammalian Drug Substance Manufacturing
Our global biopharmaceutical mammalian manufacturing network offers a range of cGMP production...
Learn More
Parenteral Drug Product Formulation Development
We offer formulation development for all biologics modalities and dosage forms. Learn more.
Learn More
Drug Product Manufacture
We offer fully integrated biologics manufacturing services from selection and qualification of the...
Learn More
Biologics Regulatory Services
Partner with our dedicated biologics regulatory team to define the optimal regulatory strategy for...
Learn More
Biologics

Related Insights

Knowledge Center
Webinar on-demand
Webinar (on-demand)
Go from DNA to IND in 11 months guaranteed* with Ibex® Design 2.0
The increasing importance of speed to clinic puts pressure on biotherapeutics product development...
Whitepaper/Executive Summary
Going From DNA To IND In 11 Months*
Biopharmaceutical companies are under increasing pressure to advance their molecules to...
KC Whitepaper thumbnail
Whitepaper/Executive Summary
How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND
Speed to clinic and to market is increasingly gaining importance among biopharmaceutical drug...
Julier pass road in Switzerland
Webinar (on-demand)
De-risk your journey to the clinic: overcome manufacturability, expression and early material...
Join Rebecca Michael, Principal Group Leader, Early Development Services at Lonza Biologics to learn...
Knowledge Center

Latest news

View all Articles
29 Mar 2023
News Release
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
View Article
29 Mar 2023
News Release
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
View Article
29 Mar 2023
News Release
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
View Article
16 Feb 2023
News Release
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
View Article
16 Feb 2023
News Release
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
View Article
16 Feb 2023
News Release
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
View Article
13 Feb 2023
Media Advisory
Lonza to Expand Early Development Services Offering into North America
View Article
13 Feb 2023
Media Advisory
Lonza to Expand Early Development Services Offering into North America
View Article
View all Articles
Ways to Contact
  • Contact Us
  • Regulatory Support
  • Locations
  • Partnering with Us
Resources
  • Knowledge Center
  • Meet the Experts
  • Upcoming Events
Terms & Conditions
  • Terms and Conditions
  • Legal Disclaimer
  • Privacy Policy
  • California CCPA Notice
  • Transparency in Coverage
Lonza.com
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
  • Sitemap
© 2023 Lonza. All rights reserved.